公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts | Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; CHIA-CHI LIN ; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. | Cancer Science | 43 | 35 | |
2019 | A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas | CHIA-CHI LIN ; Arkenau H.-T.; Lu S.; Sachdev J.; de Castro Carpe?o J.; Mita M.; Dziadziuszko R.; Su W.-C.; Bobilev D.; Hughes L.; Chan J.; Zhang Z.-Y.; Weiss G.J. | British Journal of Cancer | 17 | 12 | |
2021 | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors | Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; CHIA-CHI LIN | JTO Clinical and Research Reports | 4 | 0 | |
2013 | Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation | Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG ; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. | Cancer | 21 | 19 | |
2021 | Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors | Shiah H.-S.; Chiang N.-J.; CHIA-CHI LIN ; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. | Oncologist | 2 | 0 | |
2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 63 | 64 | |
2014 | Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer | Ying-Chun Shen ; Li C.-P.; Yen C.-J.; CHIUN HSU ; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH ; ANN-LII CHENG | Oncology (Switzerland) | 15 | 12 | |
2009 | A polymorphism in the APE1 gene promoter is associated with lung cancer risk | Lo Y.-L.; Jou Y.-S.; Hsiao C.-F.; Chang G.-C.; Tsai Y.-H.; Su W.-C.; KUAN-YU CHEN ; Chen Y.-M.; Huang M.-S.; Chi Y.H.; Chen C.-J.; Hsiung C.A. | Cancer Epidemiology Biomarkers and Prevention | 74 | 71 | |
2011 | Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers | Lo Y.-L.; Hsiao C.-F.; Jou Y.-S.; Chang G.-C.; Tsai Y.-H.; Su W.-C.; KUAN-YU CHEN ; Chen Y.-M.; Huang M.-S.; Hsieh W.-S.; Chen C.-J.; Hsiung C.A. | Lung Cancer | 53 | 50 | |
2019 | Postural Control and Interceptive Skills in Children with Autism Spectrum Disorder | LI-CHIOU CHEN ; Su W.-C.; Ho T.-L.; LU LU ; WEN-CHE TSAI ; YEN-NAN CHIU ; SUH-FANG JENG | Physical Therapy | 16 | 14 | |
2019 | Prothymosin α promotes STAT3 acetylation to induce cystogenesis in Pkd1-deficient mice | Chen Y.-C.; Su Y.-C.; Shieh G.-S.; Su B.-H.; Su W.-C.; PEI-HSIN HUANG ; Jiang S.-T.; Shiau A.-L.; Wu C.-L. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | 3 | 5 | |
2015 | R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability | Chen H.-Y.; SUNG-LIANG YU ; Ho B.-C.; KANG-YI SU ; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; CHONG-JEN YU ; KUAN-YU CHEN ; Tsai Y.-H.; Su W.-C.; HUEI-WEN CHEN ; Chen J.J.W.; Chen C.-J.; Chang G.-C.; PAN-CHYR YANG ; Li K.-C. | Journal of Clinical Oncology | 76 | 71 | |
2019 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH ; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Schütte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Atagi S.; Azuma K.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Koyama R.; Hirashima T.; Kaneda H.; Tomii K.; Fujita Y.; Seike M.; Nishimura N.; Kato T.; Ichiki M.; Saka H.; Hirano K.; Nakahara Y.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Juan-Vidal Ó.; Nadal-Alforja E.; Gil-Bazo I.; Ponce-Aix S.; Rubio-Viqueira B.; Alonso Garcia M.; Felip Font E.; Fuentes Pradera J.; Coves Sarto J.; Lin M.-C.; Su W.-C.; Hsia T.-C.; Chang G.-C.; Wei Y.-F.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. | The Lancet Oncology | 410 | 341 | |
2009 | A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting | Ho C.-L.; Su W.-C.; Hsieh R.-K.; ZHONG-ZHE LIN ; Chao T.-Y. | Japanese Journal of Clinical Oncology | 16 | 15 | |
2007 | Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-α against hepatitis C virus | Liu W.-L.; Su W.-C.; Cheng C.-W.; Hwang L.-H.; Wang C.-C.; Chen H.-L.; DING-SHINN CHEN ; Lai M.-Y. | Journal of Infectious Diseases | 32 | 29 | |
2013 | Risk factors for primary lung cancer among never smokers by gender in a matched case-control study | Lo Y.-L.; Hsiao C.-F.; Chang G.-C.; Tsai Y.-H.; Huang M.-S.; Su W.-C.; Chen Y.-M.; Hsin C.-W.; Chang C.-H.; PAN-CHYR YANG ; Chen C.-J.; Hsiung C.A. | Cancer Causes and Control | 53 | 43 | |
2021 | Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors | Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; CHIA-CHI LIN ; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. | Clinical Cancer Research | 31 | 21 | |
2021 | Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial | Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; CHIA-CHI LIN ; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. | Clinical Cancer Research | 23 | 17 | |
2020 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial | CHIH-HSIN YANG ; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. | Journal of Thoracic Oncology | 91 | 75 | |
2011 | The strategies to DVI challenges in Typhoon Morakot | Lin C.-Y.; Huang T.-Y.; Shih H.-C.; Yuan C.-H.; Chen L.-J.; Tsai H.-S.; Pan C.-H.; Chiang H.-M.; Liu H.-L.; Su W.-C.; Wu K.-T.; Chao C.-H.; Huang N.-E.; Yang K.-D.; Hsieh H.-M.; Tsai L.-C.; Linacre A.; Yu Y.-J.; Lin Y.-Y.; Chu P.-C.; JAMES CHUN-I LEE | International Journal of Legal Medicine | 14 | 9 | |